Invo Bioscience Stock Cash Flow From Operations
| INVODelisted Stock | USD 0.84 0.03 3.45% |
INVO Bioscience fundamentals help investors to digest information that contributes to INVO Bioscience's financial success or failures. It also enables traders to predict the movement of INVO Stock. The fundamental analysis module provides a way to measure INVO Bioscience's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to INVO Bioscience stock.
INVO |
INVO Bioscience Company Cash Flow From Operations Analysis
INVO Bioscience's Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current INVO Bioscience Cash Flow From Operations | (4.76 M) |
Most of INVO Bioscience's fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, INVO Bioscience is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
CompetitionIn accordance with the recently published financial statements, INVO Bioscience has (4.76 Million) in Cash Flow From Operations. This is 100.9% lower than that of the Health Care Equipment & Supplies sector and 101.3% lower than that of the Health Care industry. The cash flow from operations for all United States stocks is 100.49% higher than that of the company.
INVO Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses INVO Bioscience's direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of INVO Bioscience could also be used in its relative valuation, which is a method of valuing INVO Bioscience by comparing valuation metrics of similar companies.INVO Bioscience is currently under evaluation in cash flow from operations category among its peers.
INVO Fundamentals
| Return On Equity | -143.59 | |||
| Return On Asset | -0.27 | |||
| Profit Margin | (1.23) % | |||
| Operating Margin | (1.04) % | |||
| Current Valuation | 15.19 M | |||
| Shares Outstanding | 3.91 M | |||
| Shares Owned By Insiders | 0.60 % | |||
| Shares Owned By Institutions | 3.00 % | |||
| Number Of Shares Shorted | 1.95 K | |||
| Price To Book | 5.97 X | |||
| Price To Sales | 0.56 X | |||
| Revenue | 3.02 M | |||
| Gross Profit | 535.27 K | |||
| EBITDA | (6.63 M) | |||
| Net Income | (8.03 M) | |||
| Cash And Equivalents | 1.96 M | |||
| Cash Per Share | 0.16 X | |||
| Total Debt | 8.68 M | |||
| Debt To Equity | 0.60 % | |||
| Current Ratio | 1.99 X | |||
| Book Value Per Share | (1.59) X | |||
| Cash Flow From Operations | (4.76 M) | |||
| Short Ratio | 0.04 X | |||
| Earnings Per Share | 0.69 X | |||
| Target Price | 20.0 | |||
| Number Of Employees | 25 | |||
| Beta | 1.44 | |||
| Market Capitalization | 3.25 M | |||
| Total Asset | 20.89 M | |||
| Retained Earnings | (57.82 M) | |||
| Working Capital | (6.96 M) | |||
| Net Asset | 20.89 M |
About INVO Bioscience Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze INVO Bioscience's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of INVO Bioscience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of INVO Bioscience based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with INVO Bioscience
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if INVO Bioscience position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in INVO Bioscience will appreciate offsetting losses from the drop in the long position's value.Moving together with INVO Stock
Moving against INVO Stock
| 0.74 | MMM | 3M Company Fiscal Year End 28th of January 2025 | PairCorr |
| 0.57 | IBM | International Business Fiscal Year End 22nd of January 2025 | PairCorr |
| 0.54 | MCD | McDonalds Fiscal Year End 3rd of February 2025 | PairCorr |
| 0.41 | HYMTF | Hyundai Motor | PairCorr |
| 0.32 | TLK | Telkom Indonesia Tbk | PairCorr |
The ability to find closely correlated positions to INVO Bioscience could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace INVO Bioscience when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back INVO Bioscience - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling INVO Bioscience to buy it.
The correlation of INVO Bioscience is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as INVO Bioscience moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if INVO Bioscience moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for INVO Bioscience can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Other Consideration for investing in INVO Stock
If you are still planning to invest in INVO Bioscience check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the INVO Bioscience's history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |